drugset / Trial / NCT06185335
A Trial of the Safety and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia A
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this multicenter, two-stage, open-label study is to investigate the safety, immunogenicity, and efficacy of ANB-010 in subjects with hemophilia A. The study will have a dose-escalation design with elements of phase I/II seamless adaptive design.
Timeline
- Start
- 2023-07-26
- Primary completion
- 2025-12
- Completion
- 2033-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANB-010 | Gene therapy (AAV / viral vector) | — | Intravenous |